The phase 3 clinical trial for mFOLFIRINOX +/- CPI-613 (called AVENGER 500, NCT03504423) opened for enrollment in Chicago, IL and Winston-Salem, NC. With an expected enrollment of 500, I'd guess that it would have to open up quickly at other sites as well (ask for updated info). CPI-613 has recently been renamed devimistat.

The phase 1 results NCT01835041 were impressive, although only results from 18 patients, according to the published paper (and study participant cobraearl from this forum). CPI-613 has already been used in a variety of cancers and over 300 patients.

It appears that Rafael Pharmaceuticals confident enough that it is skipping the phase 2 trial (NCT03374852, 45 patients & never accrued) and going straight on to phase 3.

I think this one may have some legs!